SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin is trending due to recent exchange listings and its expansion to the Solana blockchain, significantly increasing its accessibility and multi-chain utility. The community is actively discussing its AI agent-powered utility on the Base ecosystem, with many anticipating a significant price appreciation while others warn of potential volatility.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl Holdings Inc. is trending after the abrupt departures of its CFO and General Counsel amid an accounting review citing material weaknesses and delayed financial filings, causing a sharp stock plunge as the community debates whether the steep sell-off is an overreaction or a severe governance concern.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology is rallying sharply following a preliminary Q3 revenue pre-announcement that significantly exceeded both previous guidance and analyst consensus, igniting community excitement and reinforcing its role as a key "picks and shovels" beneficiary in the accelerating AI infrastructure build-out.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

Fiserv is trending due to widespread anticipation of its upcoming earnings report, generating intense community discussion on whether the fintech giant will stage a significant rebound or face further pressure akin to sector peers. Bulls are highlighting recent institutional accumulation and new leadership as potential catalysts, while bears remain cautious, recalling past performance and broader concerns about AI's impact on payment processors.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is experiencing a sharp sell-off after reporting mixed Q4 earnings, where a revenue miss and conservative forward guidance overshadowed its profitability. The community is actively debating whether the market's strong negative reaction is an overdone response to broader fintech sector and macro credit concerns, or if it reflects justified apprehension regarding the company's cautious outlook.

AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases. Its mission is to develop disease-modifying therapeutics that aim to resolve fibrosis and restore organ function, enabling patients with these disorders to live fuller and healthier lives. The company was founded by Paolo Michieli, Manuela Cazzanti, Virginia Morello, Federica Caterina Linty, Michael Potter Saunders, and Hans J. W. de Haard in 2017 and is headquartered in Ghent, Belgium.

AgomAb Therapeutics NV - ADR

AgomAb Therapeutics NV (AGMB), a recent IPO, is a major talking point due to its extreme volatility and rapid price movements, with community conversation heavily focused on a potential low float and the ongoing short squeeze narrative.

Upwork, Inc. is an online marketplace which engages in the provision of businesses to find, hire, and pay freelancers for short-term and longer-term projects. Its marketplace offerings include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The company was founded by Odysseas Tsatalos and Efstratios Karamanlakis in December 2013 and is headquartered in Palo Alto, CA.

Upwork Inc

Upwork is trending lower after its latest earnings report, with disappointing Q1 guidance overshadowing beats on Q4 figures and positive long-term projections. The community is actively debating whether the significant price drop is an overreaction or signals deeper concerns about AI's impact on the gig economy and the company's future growth trajectory.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXO is gaining significant attention as investors eagerly await multiple large-scale acquisitions in the building products distribution sector, fueled by recent capital raises and CEO Brad Jacobs' aggressive growth strategy. Despite some short-term volatility from stock offerings, the community is largely bullish, anticipating substantial long-term value creation.

ETF Opportunities Trust - T-Rex 2X Inverse NVIDIA Daily Target ETF

T-Rex 2X Inverse NVIDIA Daily Target ETF

NVDQ is trending as the community anticipates a significant downturn for NVIDIA, with many viewing the semiconductor giant as massively overvalued and due for a sharp correction, especially with upcoming earnings and its stock split. Traders are aggressively leveraging this inverse ETF, driven by widespread sentiment that the 'AI bubble' is unsustainable and broader market headwinds are accumulating.

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.

Roivant Sciences Ltd

Roivant Sciences is drawing attention after reporting positive Phase 3 data for its dermatomyositis drug brepocitinib and divesting Dermavant, which has bolstered its significant cash reserves. The community is keenly discussing the substantial upside potential from ongoing LNP patent litigation involving major pharmaceutical companies, where Roivant holds a key interest through its Genevant stake.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Consensus Rating of "Moderate Buy" by Analysts

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) has been given an average rating of "Moderate Buy" by the ten brokerages that are currently covering the company, MarketBeat reports. One...

Short Interest in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Decreases By 12.5%

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) was the recipient of a large decrease in short interest in January. As of January 15th, there was short interest totaling 9,100,561 shares...

Olema Pharmaceuticals (NASDAQ:OLMA) Trading 7.7% Higher - Here's What Happened

Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price Up 7.7% - Here's Why...

Olema Pharmaceuticals (NASDAQ:OLMA) Director Sells 10,000 Shares

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) Director Cyrus Harmon sold 10,000 shares of Olema Pharmaceuticals stock in a transaction on Tuesday, January 20th. The stock was sold at an...

Olema Pharmaceuticals (NASDAQ:OLMA) Director Cyrus Harmon Sells 10,000 Shares

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) Director Cyrus Harmon sold 10,000 shares of the firm's stock in a transaction that occurred on Tuesday, January 20th. The shares were sold...

Olema Pharmaceuticals (NASDAQ:OLMA) Director Sells $101,599.68 in Stock

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) Director Cyrus Harmon sold 3,489 shares of the business's stock in a transaction on Wednesday, January 14th. The stock was sold at an...

Olema Pharmaceuticals (NASDAQ:OLMA) Director Cyrus Harmon Sells 3,489 Shares

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) Director Cyrus Harmon sold 3,489 shares of the business's stock in a transaction that occurred on Wednesday, January 14th. The shares were...

Shane William Charles Kovacs Sells 100,000 Shares of Olema Pharmaceuticals (NASDAQ:OLMA) Stock

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) insider Shane William Charles Kovacs sold 100,000 shares of the stock in a transaction that occurred on Thursday, January 15th. The stock...

Insider Selling: Olema Pharmaceuticals (NASDAQ:OLMA) Insider Sells 3,822 Shares of Stock

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) insider Shane William Charles Kovacs sold 3,822 shares of the firm's stock in a transaction that occurred on Tuesday, January 13th. The...

Insider Selling: Olema Pharmaceuticals (NASDAQ:OLMA) Insider Sells 100,000 Shares of Stock

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) insider Shane William Charles Kovacs sold 100,000 shares of Olema Pharmaceuticals stock in a transaction dated Thursday, January 15th. The...

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of next generation targeted therapies for women’s cancers. Its product candidate, OP-1250, is a novel oral therapy with combined activity as both a complete ER antagonist, or CERAN, and a selective ER degrader, or SERD, which is believed to drive deeper, more durable responses than existing therapies. The company was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.

Olema Pharmaceuticals Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

Current Price	$24.95
Prev Close	$25.36
Open	$25.36
Dividend Yield	0.00%
50-Day Moving Average	$27.50
Beta	1.01
Avg. Volume	1.2M
PE Ratio	-14.00

52-Week High	$36.26
52-Week Low	$2.86
Market Capitalization	$1.99B
EPS (Annual)	-$2.20
Price to Book	5.66
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

OLMA
Olema Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest OLMA News

OLMAOlema Pharmaceuticals Inc